Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

Protocol: 
AAAQ8124
Phase: 
I

Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

The purpose of this study is to see if IMC-CS4 (LY3022855) is safe to give to patients. We want to see how you feel when you are receiving treatment, what effects, good and/or bad, the study drug has on you and your tumor and which may be the best dose.

Are you Eligible? (Inclusion Criteria)

1. Patients with advanced solid tumors are eligible
2. Patients must have adequate bone marrow and organ function
3. Patients cannot be receiving any other anti-cancer therapy (with the exception of hormonal
therapy or HER2 targeted therapy)
4. Patients must have recovered from side effect due to prior cancer therapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States